CY1108101T1 - Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη - Google Patents

Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη

Info

Publication number
CY1108101T1
CY1108101T1 CY20081100388T CY081100388T CY1108101T1 CY 1108101 T1 CY1108101 T1 CY 1108101T1 CY 20081100388 T CY20081100388 T CY 20081100388T CY 081100388 T CY081100388 T CY 081100388T CY 1108101 T1 CY1108101 T1 CY 1108101T1
Authority
CY
Cyprus
Prior art keywords
pyrimidine
nucleozite
trizolo
preparing
compounds
Prior art date
Application number
CY20081100388T
Other languages
English (en)
Inventor
Ulf Larsson
Mattias Magnusson
Tibor Musil
Andreas Palmgren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244413&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108101(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1108101T1 publication Critical patent/CY1108101T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία ένωση πυριμιδίνης (I) χρήσιμη ως φαρμακευτικό ενδιάμεσο, σε μία διαδικασία για την παρασκευή της εν λόγω ένωσης πυριμιδίνης, σε ενδιάμεσα που χρησιμοποιούνται στην εν λόγω διαδικασία, και στη χρήση της εν λόγω ένωσης πυριμιδίνης στην παρασκευή των φαρμακευτικών.
CY20081100388T 2000-06-02 2008-04-09 Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη CY1108101T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0013488.2A GB0013488D0 (en) 2000-06-02 2000-06-02 Chemical compound
SE0002102A SE0002102D0 (sv) 2000-06-02 2000-06-06 Chemical compound
EP01937111A EP1299390B1 (en) 2000-06-02 2001-05-31 Pyrimidine compounds and their use in the preparation of a triazolo -pyrimidine carba nucleoside

Publications (1)

Publication Number Publication Date
CY1108101T1 true CY1108101T1 (el) 2014-02-12

Family

ID=26244413

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100388T CY1108101T1 (el) 2000-06-02 2008-04-09 Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη

Country Status (36)

Country Link
US (6) US7067663B2 (el)
EP (1) EP1299390B1 (el)
JP (1) JP4947870B2 (el)
KR (2) KR100802884B1 (el)
CN (3) CN100354268C (el)
AR (1) AR028605A1 (el)
AT (1) ATE386039T1 (el)
AU (4) AU6287601A (el)
BG (1) BG65866B1 (el)
BR (1) BR0111319A (el)
CA (1) CA2408914C (el)
CY (1) CY1108101T1 (el)
CZ (3) CZ302645B6 (el)
DE (1) DE60132776T2 (el)
DK (1) DK1299390T3 (el)
EE (1) EE05223B1 (el)
ES (1) ES2299487T3 (el)
GB (1) GB0013488D0 (el)
HK (1) HK1053122A1 (el)
HU (1) HU229281B1 (el)
IL (3) IL152776A0 (el)
IS (1) IS2600B (el)
MX (2) MXPA02011793A (el)
MY (1) MY131942A (el)
NO (1) NO324266B1 (el)
NZ (1) NZ522637A (el)
PL (3) PL212128B1 (el)
PT (1) PT1299390E (el)
RU (1) RU2295526C2 (el)
SE (1) SE0002102D0 (el)
SI (1) SI1299390T1 (el)
SK (1) SK286845B6 (el)
TW (1) TWI285203B (el)
UA (1) UA73182C2 (el)
WO (1) WO2001092263A1 (el)
ZA (1) ZA200209068B (el)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
SE0401001D0 (sv) * 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
SE0400873D0 (sv) * 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
GB0615620D0 (en) * 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
GB0615619D0 (en) * 2006-08-05 2006-09-13 Astrazeneca Ab Chemical process for preparation of intermediates
US7566722B2 (en) 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
ES2558843T3 (es) * 2008-09-09 2016-02-09 Astrazeneca Ab Procedimiento para preparar [1S-[1-alfa,2-alfa,3-beta(1S*,2R*),5-beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3H-1,2,3-triazolo[4,5-d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol y a sus productos intermedios
EP2336105B9 (en) 2008-09-19 2014-09-17 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
CA2694959A1 (en) * 2009-03-02 2010-09-02 Calera Corporation Gas stream multi-pollutants control systems and methods
EP2459564B1 (en) 2009-07-27 2016-09-07 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
EP2305376A1 (en) 2009-09-23 2011-04-06 Lonza Ltd. Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds
CA2788072A1 (en) 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
EP2560939A2 (en) 2010-04-20 2013-02-27 Actavis Group Ptc Ehf Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
RU2013103794A (ru) 2010-06-30 2014-08-10 Актавис Груп Птс Ехф Новые способы получения производных фенилциклопропиламина и их применение для получения тикагрелора
WO2012063126A2 (en) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
MX2013007115A (es) 2010-12-20 2014-02-10 Actavis Group Ptc Ehf Procesos novedosos para preparar derivados de triazolo[4, 5 - d] pirimidina e intermediarios de los mismos.
CA2832570A1 (en) 2011-04-06 2012-10-11 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
CN102731467B (zh) * 2011-04-15 2015-12-16 博瑞生物医药（苏州）股份有限公司 替卡格雷的中间体及制备替卡格雷的方法
BR112013028936B1 (pt) * 2011-05-13 2021-10-19 Astrazeneca Ab Processo para a preparação de benzil [(3as,4r,6s,6ar)-6-hidróxi-2,2-dimetiltetra-hidro- 3ahciclopenta[d]dioxol]-4-il]carbamato e compostos intermediários no processo
US20140206867A1 (en) 2011-06-15 2014-07-24 Actavis Group Ptc Ehf Process for Preparing Cyclopentylamine Derivatives and Intermediates Thereof
EP2570405A1 (en) 2011-09-14 2013-03-20 LEK Pharmaceuticals d.d. Synthesis of Triazolopyrimidine Compounds
HUE031673T2 (en) 2011-09-14 2017-07-28 Lek Pharmaceuticals Synthesis of triazolopyrimidine compounds
WO2013060837A1 (en) 2011-10-27 2013-05-02 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
EP2586773A1 (en) 2011-10-27 2013-05-01 LEK Pharmaceuticals d.d. Synthesis of Triazolopyrimidine Compounds
BR112014013085A2 (pt) 2011-11-30 2017-06-13 Actavis Group Ptc Ehf forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica
EP2794575B1 (en) 2011-12-23 2018-12-05 LEK Pharmaceuticals d.d. Synthesis of triazolopyrimidine compounds
EP2628721A1 (en) 2012-02-20 2013-08-21 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanecarboxylic acid
EP2644590A1 (en) 2012-03-30 2013-10-02 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
CN104603098B (zh) * 2012-03-30 2016-06-29 桑多斯股份公司 2-(3,4-二氟苯基)环丙胺衍生物和盐的合成
WO2013150495A2 (en) * 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2013163892A1 (en) * 2012-05-02 2013-11-07 Sunshine Lake Pharma Co., Ltd. Novel triazolo pyrimidine compounds and a process of preparation thereof
CN102659815B (zh) * 2012-05-04 2013-07-17 开原亨泰制药股份有限公司 一种制备选择性抗凝血药替卡格雷及其中间体的方法
CN102675321B (zh) * 2012-05-11 2014-12-10 上海皓元化学科技有限公司 一种替卡格雷的制备方法
EP2666771A1 (en) 2012-05-24 2013-11-27 LEK Pharmaceuticals d.d. Synthesis of Aminocyclopentanetriol Derivatives
WO2014023681A1 (en) * 2012-08-06 2014-02-13 Enantia, S.L. A process for the preparation of an intermediate for a triazolopyrimidine carbonucleoside
CN103588674B (zh) * 2012-08-14 2015-02-11 上海医药工业研究院 一种具有光学活性的环丙烷酰阱化合物、其制备和应用
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
CN102875537A (zh) * 2012-09-10 2013-01-16 常州制药厂有限公司 一种新的抗血栓药物的制备方法
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
US20150322071A1 (en) * 2012-12-06 2015-11-12 Brightgene Bio-Medical Technology (Suzhou) Co., Ltd Process for preparing triazole pyrimidine compounds and intermediates thereof
CN103848834B (zh) * 2012-12-06 2017-09-22 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷的方法及其中间体
CN104341402B (zh) * 2013-07-23 2018-04-27 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷中间体的方法
WO2014102830A1 (en) 2012-12-31 2014-07-03 Megafine Pharma (P) Ltd. A process for preparation of ticagrelor and intermediates thereof
CN103936767B (zh) * 2013-01-23 2016-08-03 上海医药工业研究院 一种制备化合物(1r,2s,6s,7s)-4,4-二甲基-9-苯甲基-3,5,8-三氧杂-9-氮杂三环[5.2.1.02.6]葵烷的方法
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
ITMI20130487A1 (it) 2013-03-29 2014-09-30 Chemo Res S L Alchilazione selettiva di ciclopentilalcoli
CN107573333B (zh) 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
CN103275056B (zh) * 2013-05-24 2015-06-17 浙江普洛医药科技有限公司 一种替卡格雷中间体的制备方法
WO2014195861A2 (en) * 2013-06-04 2014-12-11 Dr. Reddy’S Laboratories Limited Preparation of ticagrelor
CN104230818B (zh) * 2013-06-06 2018-01-12 郝聪梅 替卡格雷中间体的改进制备方法
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
CN103275087A (zh) * 2013-06-28 2013-09-04 南京工业大学 一种三氮唑并嘧啶类衍生物及其制备方法
CN104059069B (zh) * 2013-08-22 2016-08-10 北京康立生医药技术开发有限公司 一种替卡格雷的制备方法
CN104592237A (zh) * 2013-10-31 2015-05-06 徐州万邦金桥制药有限公司 一种抗凝血药替格瑞洛的合成方法
CN103588750B (zh) * 2013-11-07 2014-11-26 苏州明锐医药科技有限公司 替卡格雷中间体的制备方法
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN103588712B (zh) * 2013-11-08 2016-06-08 南京欧信医药技术有限公司 一种嘧啶类化合物及其制备方法、和应用
CN104710425B (zh) * 2013-12-16 2019-06-14 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛新结晶及其制备方法
CN104744424B (zh) * 2013-12-27 2018-12-25 博瑞生物医药（苏州）股份有限公司 一种替卡格雷中间体的制备方法
CN103923020A (zh) * 2014-04-02 2014-07-16 黄河三角洲京博化工研究院有限公司 一种2-丙硫基-4,6-二氯-5-氨基嘧啶的制备方法
CN103992323B (zh) * 2014-04-18 2017-03-29 南通常佑药业科技有限公司 一种替格瑞洛的制备方法
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
US10011605B2 (en) 2014-06-18 2018-07-03 Flamma Spa Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds
WO2016001851A1 (en) * 2014-07-02 2016-01-07 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN104193748A (zh) * 2014-08-14 2014-12-10 严白双 一种替卡格雷的合成方法
WO2016030704A1 (en) * 2014-08-30 2016-03-03 Cipla Limited Solid form of intermediate of ticagrelor
CN105801583A (zh) * 2014-12-31 2016-07-27 徐州万邦金桥制药有限公司 一种替格瑞洛的纯化方法
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
WO2016117852A2 (ko) * 2015-01-22 2016-07-28 동아에스티 주식회사 티카그렐러 제조방법 및 이를 위한 신규한 중간체
CN105968113B (zh) * 2015-03-12 2019-06-07 四川海思科制药有限公司 一种***并嘧啶衍生物及其应用
CN105153167B (zh) * 2015-09-06 2017-09-19 惠州信立泰药业有限公司 一种替格瑞洛结晶及含有该结晶的药物组合物
CN105198864B (zh) * 2015-10-21 2018-11-06 华仁药业股份有限公司 一种环戊基嘧啶化合物的无溶剂制备方法
WO2017072790A1 (en) * 2015-10-26 2017-05-04 Avra Laboratories Pvt. Ltd. An improved process for synthesis of ticagrelor
CN105669681A (zh) * 2016-04-11 2016-06-15 成都华宇制药有限公司 一种替格瑞洛的合成方法
CN106543191B (zh) * 2016-10-28 2019-03-01 天津红日药业股份有限公司 一种替格瑞洛制备工艺
CN107337675A (zh) * 2017-06-03 2017-11-10 湖南天济草堂制药股份有限公司 一种制备替格瑞洛的改进方法
CN107382953A (zh) * 2017-07-25 2017-11-24 安徽诺全药业有限公司 一种制备多取代环戊烷衍生物的方法
CN108689984B (zh) * 2018-05-02 2019-09-20 淮阴工学院 一种替格瑞洛中间体的生物合成方法及其中间体
CN110894184B (zh) * 2019-11-25 2022-02-18 安徽一帆香料有限公司 一种基于绿色环保的替格瑞洛中间体的制备方法
EP3919497A1 (en) 2020-06-04 2021-12-08 Zaklady Farmaceutyczne Polpharma S.A. Process for the preparation of ticagrelor
CN112457316B (zh) * 2020-11-05 2022-04-12 南通常佑药业科技有限公司 一种应用连续流反应技术制备替卡格雷高级中间体的方法
CN112724119B (zh) * 2020-12-30 2022-05-03 江苏恒沛药物科技有限公司 一种替卡格雷关键中间体的合成方法
CN115160320B (zh) * 2022-06-27 2024-05-07 南通常佑药业科技有限公司 一种手性嘧啶并***类替格瑞洛的制备方法
CN115785058B (zh) * 2022-12-09 2024-05-03 广州康瑞泰药业有限公司 一种合成替格瑞洛五元环中间体的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3040406A1 (de) * 1980-10-27 1982-05-27 Degussa Ag, 6000 Frankfurt Verfahren zur gewinnung von n-tert-alkylaminen und ameisensaeureestern
GB8916477D0 (en) * 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
JPH03118384A (ja) * 1989-07-24 1991-05-20 Glaxo Group Ltd シクロペンタン誘導体
US5654285A (en) * 1991-04-06 1997-08-05 Astra Pharmaceuticals Limited ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation
ES2078654T3 (es) 1991-04-06 1995-12-16 Astra Pharma Prod Analogos de atp.
US5817672A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
EP0840740B1 (en) * 1995-07-11 2002-05-02 AstraZeneca AB New inhibitors of platelet aggregation
WO1998028300A1 (en) * 1996-12-20 1998-07-02 Astra Pharmaceuticals Ltd. Triazolo[4,5-d]pyrimidinyl derivatives and their use as medicaments
SE9702773D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
DE69905451T2 (de) 1998-02-17 2003-11-20 Astrazeneca Uk Ltd Neue triazolo(4,5d) pyrimidinverbindungen
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
CZ20002947A3 (cs) * 1999-02-05 2000-11-15 Astrazeneca Uk Limited Nové triazolo(4,5-d)pyrimidiny, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound

Also Published As

Publication number Publication date
BG65866B1 (bg) 2010-03-31
PL392726A1 (pl) 2010-12-06
US20100004444A1 (en) 2010-01-07
AU6287601A (en) 2001-12-11
US20060041132A1 (en) 2006-02-23
US7381828B2 (en) 2008-06-03
IS2600B (is) 2010-04-15
DE60132776T2 (de) 2009-02-12
AU2010200461A1 (en) 2010-02-25
PL210375B1 (pl) 2012-01-31
SE0002102D0 (sv) 2000-06-06
CZ302645B6 (cs) 2011-08-10
UA73182C2 (en) 2005-06-15
SK16832002A3 (sk) 2003-06-03
SK286845B6 (sk) 2009-06-05
US8273879B2 (en) 2012-09-25
CZ20023919A3 (cs) 2003-05-14
IS6614A (is) 2002-11-14
EP1299390A1 (en) 2003-04-09
DE60132776D1 (de) 2008-03-27
PL392725A1 (pl) 2010-12-06
CA2408914A1 (en) 2001-12-06
NZ522637A (en) 2004-09-24
MY131942A (en) 2007-09-28
US20070049755A1 (en) 2007-03-01
KR20080003458A (ko) 2008-01-07
NO20025719L (no) 2003-02-03
PL212128B1 (pl) 2012-08-31
TWI285203B (en) 2007-08-11
MXPA02011793A (es) 2003-04-10
US20030148888A1 (en) 2003-08-07
HUP0302345A3 (en) 2007-10-29
ATE386039T1 (de) 2008-03-15
MX336939B (es) 2016-02-08
US7067663B2 (en) 2006-06-27
ES2299487T3 (es) 2008-06-01
RU2295526C2 (ru) 2007-03-20
CN1200940C (zh) 2005-05-11
AR028605A1 (es) 2003-05-14
PL211318B1 (pl) 2012-05-31
EP1299390B1 (en) 2008-02-13
KR20030007828A (ko) 2003-01-23
NO20025719D0 (no) 2002-11-28
US20110218330A1 (en) 2011-09-08
SI1299390T1 (sl) 2008-06-30
US20080234481A1 (en) 2008-09-25
ZA200209068B (en) 2003-12-02
CN1680340A (zh) 2005-10-12
CN101143864A (zh) 2008-03-19
HK1053122A1 (en) 2003-10-10
JP2003535093A (ja) 2003-11-25
HU229281B1 (en) 2013-10-28
CA2408914C (en) 2009-12-29
JP4947870B2 (ja) 2012-06-06
AU2001262876B2 (en) 2007-03-01
IL152776A (en) 2013-06-27
NO324266B1 (no) 2007-09-17
KR100802884B1 (ko) 2008-02-13
CN1432017A (zh) 2003-07-23
CN100354268C (zh) 2007-12-12
IL225893A (en) 2015-08-31
DK1299390T3 (da) 2008-05-26
EE200200669A (et) 2004-06-15
IL152776A0 (en) 2003-06-24
AU2010200461B2 (en) 2011-08-18
CZ303162B6 (cs) 2012-05-09
IL225893A0 (en) 2013-06-27
KR100814229B1 (ko) 2008-03-17
BR0111319A (pt) 2003-06-03
BG107333A (bg) 2003-07-31
WO2001092263A1 (en) 2001-12-06
PL359183A1 (en) 2004-08-23
HUP0302345A2 (hu) 2003-11-28
AU2007200776B2 (en) 2009-11-19
CZ302644B6 (cs) 2011-08-10
GB0013488D0 (en) 2000-07-26
EE05223B1 (et) 2009-10-15
PT1299390E (pt) 2008-04-17
AU2007200776A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
CY1108101T1 (el) Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη
SE9904505D0 (sv) Novel compounds
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
CY1113105T1 (el) Παραγωγα ξανθινης, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
BR0208338A (pt) Derivados de piridina
ECSP045221A (es) Sales de valsartan
SE0301653D0 (sv) Novel compounds
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
SE9804212D0 (sv) Compounds
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
CY1105699T1 (el) Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
DE60111634D1 (de) Verfahren zur herstellung von thiazolidinedion-derivaten und zwischenprodukte
NO20020914L (no) Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
NO20024679D0 (no) Krystallinsk farmasöytikum
CY1110737T1 (el) Υποκατεστημενες ενωσεις 1,5-διαμινοπενταν-3-ολης